LL-37 5 mg
Educational recon guide for a 5 mg LL-37 research vial and microgram daily unit mapping. Research use only — experimental antimicrobial/immune peptide.
Vial
5 mg
Your BAC water
2 mL
Concentration
2.50 mg/mL
Per unit
~25.0 mcg
Frequency
Once daily subcutaneous for short multi-week courses, then time off (secondary tables)
Route
Subcutaneous
Live reconstitution calculator
Defaults match this guide (5 mg + 2 mL BAC). Change water or dose and the unit tables below update automatically.
Step 1
Reconstitution
Peptide amount in the vial and how much bacteriostatic water you add.
Step 2
Your dose
This guide uses microgram-scale research doses — quick picks are in mcg (100 mcg = 0.1 mg).
Quick select (mcg) — switch units or type any value
Suggested: 30-unit barrel (smallest that fits this draw).
Your draw
Results
Total draw
4 units
Volume
0.040 mL
Doses per vial
50
Syringes needed
1
Barrel
30-unit
Fits one syringe?
Yes
30-unit · 0.3 mL
Filled to 4 u
Fill one 30-unit U-100 syringe to about 4 units (0.040 mL).
Research cycle phases
Units and volumes recompute from your Step 1 concentration (2 mL BAC → 2.50 mg/mL · 25.0 mcg/unit). Doses below are once daily during the course — not weekly.
Standard course
Secondary educational tables commonly discuss ~100–200 mcg once daily (sometimes starting ~50–125 mcg; upper community charts up to ~400 mcg) for a few weeks, then washout. Systemic LL-37 can be proinflammatory — not a casual recovery peptide.
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Days 1–14 (intro) | 100 mcg0.1 mg | 4 u | 0.04 mL100 mcg daily — lower educational start |
| Days 15–28 (standard educational) | 125 mcg0.125 mg | 5 u | 0.05 mL125 mcg daily — frequently cited secondary amount |
Alternate / higher courses
Shorter or higher daily courses discussed in research communities — not a clinical recommendation
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Higher educational · 200 mcg × 21 days | 200 mcg0.2 mg | 8 u | 0.08 mL200 mcg daily — upper common secondary range |
| Higher educational · 400 mcg × 14 days | 400 mcg0.4 mg | 16 u | 0.16 mLUpper secondary range — increased irritation / immune-effect discussions |
Supplies planner
Using the guide’s phase ladder (100 mcg → 125 mcg per injection (phase ladder)) over a 28-day course. Set a dose in Step 2 to plan supplies at your own amount.
Your recon
2 mL · 2.50 mg/mL
Dose in plan
Phase ladder
Syringe size
100-unit
Horizon
28-day course
LL-37 5 mg vials
1 vial
~3.15 mg mg total peptide over this 28-day course at 100 mcg → 125 mcg per injection (phase ladder). Each vial holds 5 mg.
Bacteriostatic water
1 × 3 mL bottle
2 mL BAC per vial × 1 vial = 2.0 mL total. Buy as 1× 3 mL bottle or 1× 10 mL bottle (whichever you stock).
U-100 insulin syringes (100-unit)
28+ syringes
About one 100-unit syringe per injection for this schedule. Keep a few spares.
Alcohol swabs & sharps
~58 swabs · 1 sharps container
Wipe vial stopper and injection site each time. Dispose needles in a proper sharps container.
Reconstitution steps
- Allow the lyophilized 5 mg LL-37 vial and bacteriostatic water to reach room temperature.
- Draw 2.0 mL bacteriostatic water (default for this guide).
- Inject BAC slowly down the inner wall of the vial — avoid blasting the powder cake.
- Gently swirl or roll until the solution is clear. Do not shake hard (foaming).
- Label with recon date and concentration (e.g. "2.5 mg/mL — 2 mL BAC").
- Refrigerate at 2–8 °C (35–46 °F), protected from light. Prefer using a reconstituted multi-dose vial within ~28 days with sterile technique.
Storage
Lyophilized
Keep dry powder cold and dark when possible (−20 °C / −4 °F preferred for long-term research stock).
Reconstituted
Refrigerate at 2–8 °C (35–46 °F). Avoid freeze–thaw of the working solution. Prefer finishing within ~28 days.
- ·Write recon date and BAC volume on the label.
- ·Protect from light during storage.
- ·Discard if cloudy, particulates, or odd odor appear after reconstitution.
Protocol notes
- ·LL-37 is the active human cathelicidin fragment (hCAP18).
- ·Calculator: 0.1 mg = 100 mcg; 0.125 mg = 125 mcg.
- ·Research use only.
Research context & considerations
LL-37 disrupts microbial membranes and modulates innate immune signaling. Systemic experimental use carries inflammation caution themes. Not an approved systemic drug via research vials.
- ·Can be proinflammatory — site reactions common.
- ·Not a substitute for medical infection or wound care.
- ·Not FDA-approved for research-vial systemic use.
- ·Pregnancy out of scope.
Catalog match
LL37
5mg x 10 vials · from $50